1. Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates
- Author
-
Dongping Ma, James J. Cali, Dieter Klaubert, Monika G. Wood, and Poncho Meisenheimer
- Subjects
Pharmacology ,Biology ,urologic and male genital diseases ,Toxicology ,digestive system ,Substrate Specificity ,Cytochrome P-450 Enzyme System ,In vivo ,Cytochrome P-450 Enzyme Inhibitors ,Humans ,Drug Interactions ,heterocyclic compounds ,Luciferase ,Luciferases ,ADME ,Luminescent Agents ,CYP3A4 ,Reproducibility of Results ,Cytochrome P450 ,General Medicine ,respiratory system ,enzymes and coenzymes (carbohydrates) ,Drug development ,Biochemistry ,Molecular Probes ,Luminescent Measurements ,Microsomes, Liver ,biology.protein ,Drug metabolism - Abstract
The cytochrome P450s (CYPs) are central to ADME studies because of their central role in drug metabolism. Proper CYP assay design and a correct understanding of CYP assay selectivity are critical for generating and interpreting biologically relevant data during drug development. Bioluminescent CYP assays use luminogenic probe substrates that have the unique property of producing photons in a second reaction with luciferase.This article presents the general design principles for in vitro CYP assays. Specifically, the article focuses on the bioluminescent approach that couples CYP activity with photon production.Highly selective luminogenic substrates for CYP1A1, CYP1A2, CYP2C9, CYP3A4, CYP3A7, CYP4A and CYP4F have been developed with utility for interrogating the roles of these enzymes in biochemical and cell-based formats. These selective substrates are part of a larger collection of probes that deliver CYP inhibition and induction data that predict in vivo drug interactions. Furthermore, they support highly sensitive, rapid and scalable assays for cell-based and cell-free biochemical applications, which offer an alternative and often enabling option over conventional assay strategies.
- Published
- 2012
- Full Text
- View/download PDF